Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke

Stroke

Volumn 34, Issue 3, 2003, Pages 671-675

  Vila, Nicolás ^a   Castillo, José ^b   Dávalos, Antonio ^c   Esteve, Anna ^d   Planas, Anna M ^e   Chamorro, Ángel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e INST D INVESTIGACIONS B   (Spain)

Author keywords

Cytokines; Inflammation; Interleukin 10; Interleukin 4; Neuroprotection; Stroke, ischemic

Indexed keywords

ANTITHROMBOCYTIC AGENT; INTERLEUKIN 10; INTERLEUKIN 4;

AGED; ARTICLE; BRAIN INFARCTION; CANADA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEEDBACK SYSTEM; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTHERMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; PRIORITY JOURNAL;

EID: 0037335934     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000057976.53301.69     Document Type: Article

References (37)

1. Castillo J, Davalos A, Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet. 1997;349:79-83.
2. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke. 1999;30:2631-2636.
3. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-I receptor antagonist in acute stroke. Ann Neurol. 1995;37:800-804.
4. Fassbender K, Rossol S, Kammer T. Daffertshofer M, Wirth S, Dollman M, Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;22:135-139.
5. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995;26:1393-1398.
6. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2001;31:2325-2329.
7. Clark WM, Zivin JA. Antileukocyte adhesion therapy: preclinical trials and combination therapy. Neurology. 1997;49(suppl 4):S32-S38.
8. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett. 1998;251:189-192.
9. Ooboshi H, Ibayashi S, Kitazono T, Yao H, Fujishima M, Iida M. Postischemic gene transfer of IL-10 protects against focal ischemia. Stroke. 2002;33:346.
10. Dietrich WD, Busto R, Bethea JR. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Exp Neurol. 1999;158:444-450.
11. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001;88:877-887.
12. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, Tarkowski A. Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997;110:492-499.
13. Pelidou SH, Kostulas N, Matusevicius D, Kivisäkk P, Kostulas V. Link H. High levels of IL-10 secreting cells are present in blood in cerebrovascular diseases. Eur J Neurol. 1999;6:437-442.
14. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci. 2001;22:289-296.
15. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001;104:746-749.
16. Adams HP, Bendixen BH, Kappelle LJ, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
17. Côté R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute study. Stroke. 1986;17:731-737.
18. Toni D, Fiorelli M, Zanette EM, Sacchetti ML, Salerno A, Argentino C, Solaro M, Fieschi C. Early spontaneous improvement and deterioration of ischemic stroke patients: a serial study with transcranial Doppler ultrasonography. Stroke. 1998;29:1144-1148.
19. Castillo J, Dávalos A, Lema M, Serena J, Noya M. Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts. Cerebrovasc Dis. 1997;7:245-250.
20. Robert C, Vermont J, Bosson JL. Formulas for threshold computations. Comput Biomed Res. 1991;24:514-519.
21. Revilla M, Obach V, Cervera A, Dávalos A, Castillo J, Chamorro A. A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002;324:29-32.
22. Castellanos M, Castillo J, García MM, Leira R, Serena J, Chamorro A, Dávalos A, Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke. 2002;33:982-987.
23. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Dávalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke. 2001;32:1154-1161.
24. Terai S, Hori T, Miake S, Tamaki K, Saishoji A. Mechanism in progressive lacunar infarction: a case report with magnetic resonance imaging. Arch Neurol. 2000;57:255-258.
25. Steinke W, Ley SC. Lacunar stroke is the major cause of progressive motor deficits. Stroke. 2002;33:1510-1516.
26. Grilli M, Barbieri I, Basudev H, Brusa R, Casati C, Lozza G. Interleukin-10 modulates neuronal threshold of vulnerability to ischemic damage. Eur J Neurosci. 2000;12:2265-2272.
27. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation. 2000;101:1019-1026.
28. Malefyt RW, Abrams J, Bennet B, Figdor CG, Vries JE. Interleukin-10 inhibits cytokine synthesis by human monocytes. J Exp Med. 1991;174:1209-1220.
29. Silvestre JS, Mallat Z, Tamarat R, Duriez M, Tedgui A, Levy BI. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res. 2001;89:259-264.
30. Tarkowski E, Rosengren L, Blomstrand C, Jensen C, Ekholm S, Tarkowski A. Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke. 1999;30:321-327.
31. Gunnett CA, Berg DJ, Faraci FM. Vascular effects of lipopolysaccharide are enhanced in interleukin-10-deficient mice. Stroke. 1999;30:2191-2196.
32. Castillo J, Rama R, Dávalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke. 2000;31:852-857.
33. Muntaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32:1759-1766.
34. Castillo J, Dávalos A, Alvarez-Sabín J, Pumar JM, Leira R, Silva Y, Montaner J, Kase CS. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology. 2002;58:624-629.
35. Koch W, Kastrati A, Böttiger C, Mehilli J, von Beckerath N, Schömig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 2001;159:137-144.
36. van Exel E, Gussekloo J, de Craen AJM, Bootsma A, Frölich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002;33:1135-1138.
37. Huhn RD, Radwanski E, O'Connell SM, Sturgill MG, Clarke L, Cody RP, Affrime M, Cutler DL. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 1996;87:699-705.